Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL9688806 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL1160009 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TDP1TRPA1 | |
| SCHEMBL1684025 | 0.83 | HMGCR (0.42) | ALDH1A1TDP1 | |
| SCHEMBL742462 | 0.80 | — | — | |
| SCHEMBL1078361 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL6032206 | 0.76 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| SCHEMBL48036 | 0.75 | — | — | |
| Methyl Alcohol SCHEMBL9770976 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TDP1TRPA1 | |
| SCHEMBL10709840 | 0.73 | — | — | |
| SCHEMBL9733363 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365584-B2 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof | POXEL (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2519527-B1 | THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-02-28 | — | — | US | disclosed |
| EP-2519527-A1 | THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | Poxel (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | disclosed |
| CN-100563651-C | With CB1-antagonistic activity of 1 | SOLVAY PHARM BV (NL) | 2009-12-02 | — | — | CN | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| EP-1307457-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| EP-0973793-B1 | NOVEL 4- HALOGENATED STEROIDS, PREPARATION METHOD AND INTERMEDIATES, APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002010172-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2002-02-07 | — | — | WO | disclosed |
| EP-0734379-B1 | 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | PARKE DAVIS (FR) | 2001-03-07 | — | — | EP | disclosed |
| EP-0995436-A2 | Ligands for sigma receptors and their therapeutical applications | PARKE-DAVIS (FR) | 2000-04-26 | — | — | EP | disclosed |
| EP-0734379-A1 | NOVEL 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | INSTITUT DE RECHERCHE JOUVEINAL (I.R.J) (FR) | 1996-10-02 | — | — | EP | disclosed |
| EP-0668273-A1 | Derivatives of 1-2-(1H-inden-3-yl)ethyl-4-(naphtalen-1-yl)-piperazin, their preparation and their therapeutical use | SYNTHELABO (FR) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995015948-A1 | NOVEL 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 1995-06-15 | — | — | WO | disclosed |
| EP-0165902-A2 | Epoxy steroids | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
| EP-0122232-A1 | 20-Spiroxanes and analogues with open ring E, process for their preparation and pharmaceutical compositions | CIBA-GEIGY AG (CH) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | PRKAB1, PRKAG1, PRKAB2 | ALDH1A1 854/4885TDP1 3178/4885TRPA1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.